This talk will examine the changes introduced by the new legislation on pharmacovigilance (Regulation 1235/2010 and Directive 2010/84) and the impact these changes have on pharmacovigilance obligations.
Audience:
In-house lawyers
• Non-UK private practitioners with pharma clients
• Patent attorneys
• Regulatory affairs professionals
• Pharmacovigilance professionals
• Commercial managers
• Compliance managers
Speakers:
David Dennis
